Lutetium-PSMA Therapy is revolutionizing advanced prostate cancer care, offering new hope where traditional treatments fall short. If you or your loved one faces metastatic or treatment-resistant prostate cancer, understanding Luetium – PSMA Therapy can be life-changing.
Read on for an in-depth guide to eligibility, advantages, and why you should trust leading hospitals for this cutting-edge treatment.
What is Lutetium-PSMA Therapy?
Lutetium-177 PSMA therapy is a form of targeted radioligand treatment designed for men with advanced or metastatic prostate cancer. It works by combining Lutetium-177, a radioactive element, with a molecule that binds to the Prostate-Specific Membrane Antigen (PSMA) present on cancer cells. After intravenous administration, this compound travels through the bloodstream, selectively attaching to PSMA-positive cancer cells and releasing radiation to destroy them with minimal damage to healthy tissues.
Who is Eligible for Lutetium-PSMA Therapy?
This therapy is primarily indicated for patients who:
- Are age 18 or older
- Have advanced, metastatic prostate cancer not responding to hormonal therapy or chemotherapy
- Have confirmed PSMA-positive tumors on a PET/CT scan (PSMA imaging is mandatory for therapy selection)
- Have adequate kidney and bone marrow function (as checked by blood tests and scans)
- Do not have serious conditions such as severe liver or kidney failure
Most frequently, it’s recommended for those with castration-resistant prostate cancer (CRPC) who have already tried other systemic therapies with limited success.
Not suitable for: Patients with poor organ function, certain blood conditions, or tumors that do not express PSMA strongly on imaging.
The Treatment Process
- Preliminary evaluation (consultation, lab tests, PSMA PET scan)
- Outpatient infusion of Lutetium-177 PSMA compound (no surgical incision needed)
- Monitoring for 24 hours and periodic follow-up imaging to assess tumor response
- Repeat treatments every 6-8 weeks, typically a series of four cycles
Key Benefits of Luetium – PSMA Therapy
- High precision: Targets only PSMA-expressing cancer cells, sparing healthy tissue
- Better tolerability: Side effects are generally mild—fatigue, dry mouth, nausea, or transient low blood counts
- Effective for advanced disease: Can lead to significant shrinkage of tumors and extended survival in 60–80% of patients not helped by other therapies
- Improved quality of life: Controls pain, symptoms, and cancer spread, allowing more active and comfortable daily living
- Outpatient therapy: Reduces need for long hospital stays or recovery
Why Choose Valentis Cancer Hospital?
Valentis Cancer Hospital is a top choice for patients seeking Lutetium-PSMA and other advanced therapies:
- Expertise: Multidisciplinary teams comprising nuclear medicine, oncology, imaging, and supportive care experts.
- Advanced diagnostics: PSMA PET-CT imaging, kidney and bone marrow function assessments for safe patient selection.
- Integrated approach: Seamless transition between diagnostics, therapy, follow-up, and symptom management.
- Cutting-edge technology: Access to the latest protocols and compassionate patient care.
- Reputation: Recognized as the best cancer hospital in India and a leader in precision cancer therapies.
Conclusion
Luetium – PSMA Therapy represents a new era in targeted, effective care for advanced prostate cancer in India. For those previously running out of options, it delivers fresh hope, measurable outcomes, and a path to better quality of life.